论文部分内容阅读
目的:探讨采用Viatorr支架行经颈静脉肝内门体静脉分流术（TIPS）治疗肝硬化门静脉高压的临床疗效和安全性。方法:2016年3月至2018年8月，43例肝硬化门静脉高压患者在TIPS术中置入Viatorr支架，定期随访血清学指标、彩超、胃镜以及再出血、腹水和肝性脑病情况，门静脉压力、肝肾功能、凝血指标比较采用配对n t检验，Kaplan-Meier曲线计算支架通畅率、肝性脑病发生率、再出血率及生存率。n 结果:所有患者手术成功率100%，门静脉压力梯度由术前（25.57±5.50）mmHg降至术后（9.76±2.92）mmHg。术后1个月丙氨酸转氨酶（ALT）较术前明显升高，但在术后3、6个月与术前无明显差异；术后1、3、6个月总胆红素、血氨、凝血酶原时间较术前有所升高，白蛋白较术前无明显变化，肌酐和尿素氮较术前有所降低。患者术后12、24个月累积再出血率分别为0、9%；26例腹水患者中，22例（84.6%）腹水完全消失，3例（11.5%）腹水明显减少。术后3、6、12、24个月肝性脑病累积发生率分别为11.6%、17.3%、21.9%、21.9%；术后12、24个月支架功能障碍累积发生率分别为5.6%、23.7%。术后12个月及24个月累积生存率均为91.9%。结论:采用Viatorr支架行TIPS手术可有效降低门静脉压力及再出血率，提高肝内分流道通畅率，并不增加术后肝性脑病发生风险，且术后累积生存率较高。“,”Objective:To investigate the clinical efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) with the use of Viator stent in the treatment of cirrhotic portal hypertension.Methods:43 cases with cirrhotic portal hypertension were implanted with Viatorr stent during TIPS procedure from March 2016 to August 2018. Serological indicators, color Doppler ultrasound, gastroscopy, rebleeding, ascites and hepatic encephalopathy were regularly followed up. Portal venous pressure, liver and kidney function, coagulation indexes were compared by t-test. Stent patency rate, hepatic encephalopathy incidence, rebleeding rate and survival rate were calculated by Kaplan-Meier curve.Results:TIPS procedure success rate was 100% in all patients. Portal pressure gradient was decreased from (25.57 ± 5.50) mmHg to (9.76 ± 2.92) mmHg before and after operation. Alanine aminotransferase (ALT) was significantly higher at 1 month after operation than before operation, but there was no significant difference between 3 and 6 months after and before operation. Total bilirubin, serum ammonia and prothrombin time at 1, 3, and 6 months after operation were higher than before operation. Albumin had no significant change compared with before operation, and creatinine and urea nitrogen were lower than before operation. The cumulative rebleeding rates at 12 and 24 months after operation was 0% and 9%, respectively. Of the 26 patients with ascites, 22 cases (84.6%) had complete disappearance of ascites and 3 (11.5%) had significant decrease of ascites. The cumulative incidence of hepatic encephalopathy at 3, 6, 12 and 24 months after surgery was 11.6%, 17.3%, 21.9% and 21.9%, respectively. The cumulative incidence of stent dysfunction at 12 and 24 months after surgery was 5.6% and 23.7%, respectively. The cumulative survival rate at 12 months and 24 months after surgery was 91.9%.Conclusion:TIPS procedure with Viatorr stent can effectively reduce portal pressure and rebleeding rate, improve intrahepatic shunt patency rate, and will not increase the risk of postoperative hepatic encephalopathy, and has a higher cumulative survival rate.